A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

被引：0

作者：

Sen, S. ^{[1
]}

Spira, A. I. ^{[2
]}

Sommerhalder, D. ^{[3
]}

Meric-Bernstam, F. ^{[4
]}

Subbiah, V. ^{[4
]}

Berlin, J. D. ^{[5
]}

Parikh, A. ^{[6
]}

Cecchini, M. ^{[7
]}

Sanborn, R. E. ^{[8
]}

Chablani, P. V. ^{[9
]}

Peoples, G. E. ^{[10
]}

Schurpf, T. ^{[11
]}

Dillon, L. A. ^{[12
]}

Clifton, G. T. ^{[13
]}

Eder, J. P. ^{[14
]}

Tolcher, A. W. ^{[15
]}

机构：

[1] NEXT Oncol TM, Phase 1 Trial Ctr, San Antonio, TX USA

[2] Virginia Canc Specialist, Res Inst, Fairfax, VA USA

[3] NEXT Oncol TM, Oncol, San Antonio, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Dept, Houston, TX USA

[5] Vanderbilt Univ, Dept Med, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA

[6] MGH Massachusetts Gen Hosp, Dept Gastrointestinal Oncol, Boston, MA USA

[7] Yale Univ, Yale Canc Ctr, Oncol, Sch Med, New Haven, CT USA

[8] Earle A Chiles Res Inst, Robert Franz Canc Ctr, Med Oncol, Portland, OR USA

[9] UPMC Hillman Canc Ctr, Med Oncol, Pittsburgh, PA USA

[10] Lumabridge LLC, Dept Surg, San Antonio, TX USA

[11] Parthenon Therapeut, Prot Sci, Cambridge, MA USA

[12] Parthenon Therapeut, Translat Med, Cambridge, MA USA

[13] Parthenon Therapeut, Clin Sci, Boston, MA USA

[14] Parthenon Therapeut, Clin Dev, Boston, MA USA

[15] NEXT Oncol TM, Clin Res Director, San Antonio, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2976

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1079TiP

引用

页码：S649 / S650

页数：2

共 50 条

[31] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
Carneiro, Ana
Hahn, Amanda
Ellmark, Peter
Enell Smith, Karin
Schultz, Lena
Ambarkhane, Sumeet
Yachnin, Jeffrey
Ullenhag, Gustav J.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
[32] Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Naing, Aung
Infante, Jeffrey
Goel, Sanjay
Burris, Howard
Black, Chelsea
Marshall, Shannon
Achour, Ikbel
Barbee, Susannah
May, Rena
Morehouse, Chris
Pollizzi, Kristen
Song, Xuyang
Steele, Keith
Elgeioushi, Nairouz
Walcott, Farzana
Karakunnel, Joyson
LoRusso, Patricia
Weise, Amy
Eder, Joseph
Curti, Brendan
Oberst, Michael
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
[33] Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Patnaik, Amita
Kang, S. Peter
Rasco, Drew
Papadopoulos, Kyriakos P.
Elassaiss-Schaap, Jeroen
Beeram, Muralidhar
Drengler, Ronald
Chen, Cong
Smith, Lon
Espino, Guillermo
Gergich, Kevin
Delgado, Liliana
Daud, Adil
Lindia, Jill A.
Li, Xiaoyun Nicole
Pierce, Robert H.
Yearley, Jennifer H.
Wu, Dianna
Laterza, Omar
Lehnert, Manfred
Iannone, Robert
Tolcher, Anthony W.
CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4286 - 4293
[34] Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Idowu, O.
Craigen, J.
Svetlik, S.
Veal, J.
Jamieson, D.
ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
[35] A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies (vol 16, pg 1915, 2010)
Kuenen, B.
Witteveen, P. O.
Ruijter, R.
Giaccone, G.
Dontabhaktuni, A.
Fox, F.
Katz, T.
Youssoufian, H.
Zhu, J.
Rowinsky, E. K.
Voest, E. E.
CLINICAL CANCER RESEARCH, 2010, 16 (18) : 4681 - 4681
[36] FIRST-IN-HUMAN PHASE I TRIAL OF IBI188, AN ANTI-CD47 TARGETING MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS
Lakhani, Nehal
Orloff, Marlana
Fu, Siqing
Liu, Ying
Wang, Yan
Zhou, Hui
Lin, Kedan
Liu, Fang
Yan, Shuling
Patnaik, Amita
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A180 - A180
[37] Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies
Rothenberg, M. L.
Poplin, E.
LoRusso, P.
Yu, E.
Schwartz, J.
Fox, F.
Mehnert, J.
Sandler, A. B.
Rowinsky, E.
Higano, C. S.
EJC SUPPLEMENTS, 2008, 6 (12): : 174 - 175
[38] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
Ullenhag, Gustav J.
Yachnin, Jeffrey
Carneiro, Ana
Elison, Emma
Carlsson, Malin
Russell, Charlotte Astrid
Smith, Karin Enell
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
Shimizu, Toshio
Powderly, John
Abdul Razak, Albiruni
Lorusso, Patricia
Miller, Kathy D.
Kao, Steven
Kongpachith, Sarah
Tribouley, Catherine
Graham, Michelle
Stoll, Brian
Patel, Maulik
Sahtout, Mohammad
Blaney, Martha
Leibman, Rachel
Golan, Talia
Tolcher, Anthony
FRONTIERS IN ONCOLOGY, 2024, 14
[40] A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)
Lakhani, N.
Cosman, R.
Banerji, U.
Rasco, D.
Tomaszewska-Kiecana, M.
Garralda, E.
Kornacki, D.
Li, J.
Tian, C.
Bourayou, N.
Powderly, J.
ESMO OPEN, 2024, 9 (04)

← 1 2 3 4 5 →